Monopar Therapeutics MNPR 深 沪
交易中 10-08 12:13:28 美东时间
82.76
-1.020
-1.22%
华盛通- 最 高83.795
- 今 开82.48
- 成交量 8.04万股
- 最 低 81.40
- 昨 收 83.78
- 总市值 5.55亿
- 52周最高 124.82
- 市盈率 静 --
- 换手率 1.20%
- 52周最低 50.07
- 委 比 -33.33%
- 总股本 671.22万
- 历史最高 240.00
- 量 比 1.37
- 振 幅 2.86%
- 历史最低 1.3695
- 每 手 1
- 风险率 20.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Adobe绩后获多家大行齐升目标价！最高看多至270美元；甲骨文绩后现多空分歧
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从10美元升至10.5美元；摩根士丹利：维持Aurora Innovation"超配"评级，目标价从14美元升至18美元
09-14 16:05
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.
09-11 21:48
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Monopar cut to Neutral at Cantor on valuation
Monopar Therapeutics (MNPR) traded lower on Thursday after Cantor Fitzgerald downgraded the clinical-stage biopharma to Neutral from Overweight, arguing that the stock is fairly valued at current leve...
08-14 01:11
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Cantor Fitzgerald analyst Kristen Kluska downgraded Monopar Therapeutics Inc (NASDAQ:MNPR) from O...
08-14 00:09
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.
08-13 03:48
Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.56) by 10.71 percent. This is a 77.14 percent decrease over losses of $(0.35) per share from the same period last year.
08-12 21:32
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics announced second quarter 2026 financial results and updates on ALXN1840 for Wilson Disease. The company initiated a rolling NDA submission for ALXN1840, received Rare Pediatric Disease (RPD) designation, and presented positive Phase 3 and Phase 2 clinical data. Financially, the company reported a net loss of $5.3 million and increased R&D and G&A expenses. Cash reserves of $134.3 million are expected to support operations thr...
08-12 13:30
美股大行评级 | 富国银行上调闪迪目标价从1250美元升至1620美元；最高132美元！高盛、大小摩等多家机构上调通用汽车目标价
今日重点评级关注：HC Wainwright & Co.：维持IREN"买入"评级，目标价从85美元升至90美元；BTIG：维持FTAI Aviation"买入"评级，目标价从340美元升至400美元
07-23 13:42
